Clear Cell Renal Cell Carcinoma Clinical Trials in San Diego, California

5 studies are recruiting for clear cell renal cell carcinoma in San Diego, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

   This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC San Diego Medical Center - Bankers Hill, San Diego, California

   Locations

   162 in total

   Run by

   Pfizer

   See if you can join NCT07227415 on ClinicalTrials.gov

2. Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

   This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UC San Diego Medical Center - Hillcrest, San Diego, California

   Locations

   425 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT06661720 on ClinicalTrials.gov

3. A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

   The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, San Diego, California

   Locations

   25 in total

   Run by

   Arcus Biosciences, Inc.

   See if you can join NCT05536141 on ClinicalTrials.gov

4. Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

   The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monother…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEO-811 San Diego Site, San Diego, California

   Locations

   12 in total

   Run by

   Neomorph, Inc

   See if you can join NCT07300241 on ClinicalTrials.gov

5. A Beta-only IL-2 ImmunoTherapY Study

   This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sharp Memorial Hospital, San Diego, California

   Locations

   27 in total

   Run by

   Medicenna Therapeutics, Inc.

   See if you can join NCT05086692 on ClinicalTrials.gov